Developing potential breakthrough therapies for patients with cancer by targeting cancer-specific vulnerabilities & co-dependencies in the tumor microenvironment

Developing potential breakthrough therapies for patients with cancer by targeting cancer-specific vulnerabilities & co-dependencies in the tumor microenvironment​

.01

About

Harnessing our vast network, strategic resources, and operational expertise, the Sporos team of highly accomplished leaders identifies novel disease mechanisms and catalyzes the development of potential breakthrough medicines.

.02

Team

With a mix of impressive scientific expertise and operational understanding of the biotech industry, as well as deep roots in the burgeoning Houston biotech ecosystem, the Sporos leadership team is uniquely positioned to identify and advance a growing pipeline of first-in-class treatment options.

.03

Pipeline

We are advancing a diversified pipeline of clinical and preclinical-stage assets at Sporos and our portfolio companies with a focus on cancer and serious immune disease.  

Clinical stage company focused on breakthrough medicines for cancer, inflammation, and fibrosis.

Development stage company focused on novel immune regulatory antibody therapeutics for cancer and autoimmune and infectious diseases.

Pioneering the discovery and development of novel small molecule inhibitors targeting cellular transporters at the nexus of tumor metabolism and immunity.

Development stage company focused on novel therapies targeting factors produced by cancer-associated fibroblasts, critical for tumor growth.

.04

Recent News

View the latest news and press releases from Sporos Bioventures

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

Houston, TX – May 26, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused …

Read More →

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

Houston, TX – April 21, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused …

Read More →

Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research

Houston, TX – April 7, 2022 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused …

Read More →

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive …

Read More →
Scroll to Top